159 related articles for article (PubMed ID: 34880215)
1. Ibrutinib as a potential therapeutic for cocaine use disorder.
Huggett SB; Hatfield JS; Walters JD; McGeary JE; Welsh JW; Mackay TFC; Anholt RRH; Palmer RHC
Transl Psychiatry; 2021 Dec; 11(1):623. PubMed ID: 34880215
[TBL] [Abstract][Full Text] [Related]
2. Repurposing ketamine to treat cocaine use disorder: integration of artificial intelligence-based prediction, expert evaluation, clinical corroboration and mechanism of action analyses.
Gao Z; Winhusen TJ; Gorenflo M; Ghitza UE; Davis PB; Kaelber DC; Xu R
Addiction; 2023 Jul; 118(7):1307-1319. PubMed ID: 36792381
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory mediators and dual depression: Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders.
García-Marchena N; Barrera M; Mestre-Pintó JI; Araos P; Serrano A; Pérez-Mañá C; Papaseit E; Fonseca F; Ruiz JJ; Rodríguez de Fonseca F; Farré M; Pavón FJ; Torrens M
PLoS One; 2019; 14(3):e0213791. PubMed ID: 30870525
[TBL] [Abstract][Full Text] [Related]
4. Abnormal neuroanatomical patterns as potential diagnostic biomarkers for cocaine use disorder.
Xu H; Xu C; Guo Y; Hu Y; Bai G; Du M
Addict Biol; 2023; 28(11):e13348. PubMed ID: 37855070
[TBL] [Abstract][Full Text] [Related]
5. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder.
DeVito EE; Carroll KM; Babuscio T; Nich C; Sofuoglu M
J Subst Abuse Treat; 2019 Dec; 107():29-37. PubMed ID: 31757262
[TBL] [Abstract][Full Text] [Related]
6. GABAergic polygenic risk for cocaine use disorder is negatively correlated with precuneus activity during cognitive control in African American individuals.
Yang BZ; Balodis IM; Kober H; Worhunsky PD; Lacadie CM; Gelernter J; Potenza MN
Addict Behav; 2021 Mar; 114():106695. PubMed ID: 33153773
[TBL] [Abstract][Full Text] [Related]
7. Regional and source-based patterns of [
Worhunsky PD; Matuskey D; Gallezot JD; Gaiser EC; Nabulsi N; Angarita GA; Calhoun VD; Malison RT; Potenza MN; Carson RE
Neuroimage; 2017 Mar; 148():343-351. PubMed ID: 28110088
[TBL] [Abstract][Full Text] [Related]
8. Do gene expression findings from mouse models of cocaine use recapitulate human cocaine use disorder in reward circuitry?
Huggett SB; Bubier JA; Chesler EJ; Palmer RHC
Genes Brain Behav; 2021 Feb; 20(2):e12689. PubMed ID: 32720468
[TBL] [Abstract][Full Text] [Related]
9. Emotion recognition in individuals with cocaine use disorder: the role of abstinence length and the social brain network.
Rabin RA; Parvaz MA; Alia-Klein N; Goldstein RZ
Psychopharmacology (Berl); 2022 Apr; 239(4):1019-1033. PubMed ID: 34089343
[TBL] [Abstract][Full Text] [Related]
10. Convergent abnormalities in striatal gene networks in human cocaine use disorder and mouse cocaine administration models.
Mews P; Cunningham AM; Scarpa J; Ramakrishnan A; Hicks EM; Bolnick S; Garamszegi S; Shen L; Mash DC; Nestler EJ
Sci Adv; 2023 Feb; 9(6):eadd8946. PubMed ID: 36763659
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation in cocaine use disorder-An epigenome-wide approach in the human prefrontal cortex.
Poisel E; Zillich L; Streit F; Frank J; Friske MM; Foo JC; Mechawar N; Turecki G; Hansson AC; Nöthen MM; Rietschel M; Spanagel R; Witt SH
Front Psychiatry; 2023; 14():1075250. PubMed ID: 36865068
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis.
Blevins D; Seneviratne C; Wang XQ; Johnson BA; Ait-Daoud N
Drug Alcohol Depend; 2021 Nov; 228():109074. PubMed ID: 34600264
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of plasma-free endocannabinoids and their congeners in abstinent cocaine addicts seeking outpatient treatment: impact of psychiatric co-morbidity.
Pavón FJ; Araos P; Pastor A; Calado M; Pedraz M; Campos-Cloute R; Ruiz JJ; Serrano A; Blanco E; Rivera P; Suárez J; Romero-Cuevas M; Pujadas M; Vergara-Moragues E; Gornemann I; Torrens M; de la Torre R; Rodríguez de Fonseca F
Addict Biol; 2013 Nov; 18(6):955-69. PubMed ID: 24283982
[TBL] [Abstract][Full Text] [Related]
14. Remarkable Reduction of Cocaine Use in Dual Disorder (Adult Attention Deficit Hyperactive Disorder/Cocaine Use Disorder) Patients Treated with Medications for ADHD.
Manni C; Cipollone G; Pallucchini A; Maremmani AGI; Perugi G; Maremmani I
Int J Environ Res Public Health; 2019 Oct; 16(20):. PubMed ID: 31618876
[No Abstract] [Full Text] [Related]
15. Neurite orientation dispersion and density imaging in cocaine use disorder.
Rasgado-Toledo J; Shah A; Ingalhalikar M; Garza-Villarreal EA
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 113():110474. PubMed ID: 34758367
[TBL] [Abstract][Full Text] [Related]
16. Hypothalamic-pituitary-adrenal axis activity in post-traumatic stress disorder and cocaine use disorder.
Hadad NA; Schwendt M; Knackstedt LA
Stress; 2020 Nov; 23(6):638-650. PubMed ID: 32835581
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of cocaine use disorders in humans.
Fernàndez-Castillo N; Cabana-Domínguez J; Corominas R; Cormand B
Mol Psychiatry; 2022 Jan; 27(1):624-639. PubMed ID: 34453125
[TBL] [Abstract][Full Text] [Related]
18. Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.
Anastasio NC; Sholler DJ; Fox RG; Stutz SJ; Merritt CR; Bjork JM; Moeller FG; Cunningham KA
Neuropharmacology; 2020 May; 168():108009. PubMed ID: 32145488
[TBL] [Abstract][Full Text] [Related]
19. A serotonergic biobehavioral signature differentiates cocaine use disorder participants administered mirtazapine.
Ma L; Cunningham KA; Anastasio NC; Bjork JM; Taylor BA; Arias AJ; Riley BP; Snyder AD; Moeller FG
Transl Psychiatry; 2022 May; 12(1):187. PubMed ID: 35523779
[TBL] [Abstract][Full Text] [Related]
20. Cocaine Use Disorder (CUD): Current Clinical Perspectives.
Schwartz EKC; Wolkowicz NR; De Aquino JP; MacLean RR; Sofuoglu M
Subst Abuse Rehabil; 2022; 13():25-46. PubMed ID: 36093428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
